Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4358)	7/26/2001 2:05:26 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Hi Peter, The street never ceases to amaze me. SCIO is up a little better than 10% at this point today with a range so far from $18.30 to $20.95 From the conf call: SCIO-469 or the P38 Kinase Inhibitor Ph II trial will probably start during 4Q. [Seems far too early and far too abstract to have any affect on stock price.] Natrecor factory passed FDA Muster. [old news, already announced]. No revenue estimates for Natrecor will be given until the October call. [Mike had hoped to get these now.] Not much new label info. In the Q&A, one analyst asked whether there was any "Black Box" warning discussions with the FDA yet. Response was "No. ...and we don't believe it's too likely, but who knows". [I don't remember what the "black box warning" context is from prior calls, so I can't accurately judge the significance of this tiny bit of info.] And SCIO reiterated that it expects full FDA Natrecor approval within the next few weeks. [Had previously stated near Mid August.] All in all, I didn't hear anything whatsoever that I felt would move the stock which couldn't have already been known with reasonable certainty. But then, I still don't understand why the street sold the stock down past the mid 20s. Sign me, "baffled", Ian.